Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Trial details
- Registry ID
- NCT04006119
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive GlioblastomaNCT04006119 | Alaunos Therapeutics | Phase 2 | Terminated | 2021-08-05Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |